Enhanced Equity Fund Invests in Specialty Therapeutic

Enhanced Equity Fund has invested in Specialty Therapeutic Care, a Houston specialty pharmacy that serves patients with chronic bleeding disorders. Financial terms weren’t announced. Enhanced Equity Fund, of New York, is a PE firm.

PRESS RELEASE

Enhanced Equity Fund (“EEF”), a private equity firm investing in leading, lower-middle market healthcare services companies, today announced its investment in Specialty Therapeutic Care (“STC”), a rapidly growing national specialty pharmacy, providing healthcare management, pharmacy and delivery services to patients primarily suffering from chronic bleeding disorders, such as hemophilia. The transaction was led by Christopher J. Garcia and Kenton Rosenberry, both Partners at EEF.
“STC delivers differentiated, high-touch service to its patients and represents a very strong platform within the specialty pharmacy industry.” said Mr. Rosenberry. “We look forward to partnering with the dedicated and focused management team of STC to further the company’s rapid growth through a continued commitment to excellent patient care.”
“We are committed to expanding upon STC’s exceptional growth, which has averaged almost 100% annually since 2006, and will provide the necessary capital to take advantage of increasing organic growth opportunities as well as fund strategic acquisitions, with the ultimate goal of establishing STC as a leader within the specialty pharmaceutical industry serving a number of different disease states and patient communities,” added Mr. Garcia.
“We chose to partner with EEF given their collective experience and relationships within the industry and feel confident that they will provide us with the guidance and resources necessary to realize the many opportunities for growth available in the specialty pharmaceutical sector,” said Matt Angell, Founder and President of STC.
In June of this year, EEF held a final close on its second fund, Enhanced Equity Fund II, L.P. (“EEF II”), for a total of $380 million, which was oversubscribed by 18%. EEF II will continue to utilize the first fund’s investment strategy of investing in growth companies within the healthcare sector and building industry leaders through operational excellence, organic growth and strategic add-on acquisitions. EEF will utilize its extensive network, experience and knowledge within healthcare to identify and execute successful investments. With the close of EEF II, the firm manages in excess of $600 million of committed equity capital and is actively seeking to make investments in profitable, growing healthcare businesses.
STC represents the first investment for EEF out of its second fund.
About Specialty Therapeutic Care
STC, founded in 2006 and based in Houston, TX, is a national specialty pharmacy, currently licensed in 19 States, and a leading distributor of various blood products and pharmaceuticals to treat a wide array of bleeding disorders. The Company is dedicated to meeting the specialized needs of individuals with chronic or life-threatening illnesses and is continually devoted to providing efficient and compassionate treatment that extends beyond traditional service parameters by actively working with patients, physicians, health plans, patient advocacy organizations and pharmaceutical companies. STC’s commitment to superior patient care and service has driven outstanding revenue growth of almost 100% annually since 2006.
About Enhanced Equity Fund
EEF, based in New York, NY and founded in 2005 by Andrew M. Paul, is a private equity fund, with over $600 million of assets under management, focused on providing capital to lower-middle market growth companies in the healthcare services industry. The firm’s investment philosophy and strategy is to invest in smaller, high-growth companies and partner with successful entrepreneurs and management teams to build value through internal growth and acquisitions. EEF is currently investing its second fund, Enhanced Equity Fund II, L.P.

Enhanced Equity Fund (“EEF”), a private equity firm investing in leading, lower-middle market healthcare services companies, today announced its investment in Specialty Therapeutic Care (“STC”), a rapidly growing national specialty pharmacy, providing healthcare management, pharmacy and delivery services to patients primarily suffering from chronic bleeding disorders, such as hemophilia. The transaction was led by Christopher J. Garcia and Kenton Rosenberry, both Partners at EEF.
“STC delivers differentiated, high-touch service to its patients and represents a very strong platform within the specialty pharmacy industry.” said Mr. Rosenberry. “We look forward to partnering with the dedicated and focused management team of STC to further the company’s rapid growth through a continued commitment to excellent patient care.”
“We are committed to expanding upon STC’s exceptional growth, which has averaged almost 100% annually since 2006, and will provide the necessary capital to take advantage of increasing organic growth opportunities as well as fund strategic acquisitions, with the ultimate goal of establishing STC as a leader within the specialty pharmaceutical industry serving a number of different disease states and patient communities,” added Mr. Garcia.
“We chose to partner with EEF given their collective experience and relationships within the industry and feel confident that they will provide us with the guidance and resources necessary to realize the many opportunities for growth available in the specialty pharmaceutical sector,” said Matt Angell, Founder and President of STC.
In June of this year, EEF held a final close on its second fund, Enhanced Equity Fund II, L.P. (“EEF II”), for a total of $380 million, which was oversubscribed by 18%. EEF II will continue to utilize the first fund’s investment strategy of investing in growth companies within the healthcare sector and building industry leaders through operational excellence, organic growth and strategic add-on acquisitions. EEF will utilize its extensive network, experience and knowledge within healthcare to identify and execute successful investments. With the close of EEF II, the firm manages in excess of $600 million of committed equity capital and is actively seeking to make investments in profitable, growing healthcare businesses.
STC represents the first investment for EEF out of its second fund.
About Specialty Therapeutic Care
STC, founded in 2006 and based in Houston, TX, is a national specialty pharmacy, currently licensed in 19 States, and a leading distributor of various blood products and pharmaceuticals to treat a wide array of bleeding disorders. The Company is dedicated to meeting the specialized needs of individuals with chronic or life-threatening illnesses and is continually devoted to providing efficient and compassionate treatment that extends beyond traditional service parameters by actively working with patients, physicians, health plans, patient advocacy organizations and pharmaceutical companies. STC’s commitment to superior patient care and service has driven outstanding revenue growth of almost 100% annually since 2006.
About Enhanced Equity Fund
EEF, based in New York, NY and founded in 2005 by Andrew M. Paul, is a private equity fund, with over $600 million of assets under management, focused on providing capital to lower-middle market growth companies in the healthcare services industry. The firm’s investment philosophy and strategy is to invest in smaller, high-growth companies and partner with successful entrepreneurs and management teams to build value through internal growth and acquisitions. EEF is currently investing its second fund, Enhanced Equity Fund II, L.P.